TY  - JOUR 
AU  - Mitjavila, M.
AU  - Jimenez-Fonseca, P.
AU  - Belló, P.
AU  - Pubul Nuñez, Virginia
AU  - Percovich, J.C.
AU  - Garcia-Burillo, A.
AU  - Hernando, J.
AU  - Arbizu, J.
AU  - Rodeño, E.
AU  - Estorch, M.
AU  - Llana, B.
AU  - Castellón, M.
AU  - García-Cañamaque, L.
AU  - Gajate, P.
AU  - Riesco, M.C.
AU  - Miguel, M.B.
AU  - Balaguer-Muñoz, D.
AU  - Custodio, A.
AU  - Cano, J.M.
AU  - Repetto, A.
AU  - Garcia-Alonso, P.
AU  - Muros, M.A.
AU  - Vercher-Conejero, J.L.
AU  - Carmona-Bayonas, A.
PY  - 2023
SN  - 1619-7089
UR  - http://hdl.handle.net/20.500.11940/21425
AB  - Background: Peptide receptor radionuclide therapy (PRRT) is one of the most promising therapeutic strategies in neuroendocrine neoplasms (NENs). Nevertheless, its role in certain tumor sites remains unclear. This study sought to elucidate the efficacy...
LA  - eng
KW  - Humans
KW  - Octreotide
KW  - Neuroendocrine Tumors
KW  - Prognosis
KW  - Receptors, Somatostatin
KW  - Pheochromocytoma
KW  - Paraganglioma
KW  - Adrenal Gland Neoplasms
KW  - Organometallic Compounds
TI  - Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study
DO  - 10.1007/s00259-023-06166-8
T2  - European Journal of Nuclear Medicine and Molecular Imaging
M2  - 2486
KW  - AS Santiago
KW  - CHUS
VL  - 50
ER  -